Category Archives: Mesenchymal Stem Cells

NEW YORK, May 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company focused on cell based therapies, announced today that Company management will present at six conferences in June. International Society for Cellular Therapy Annual Meeting National Investment Banking Association Conference International Society for Stem Cell Research 10th Annual Meeting The Biotechnology Industry Organization (BIO) International Conference Alliance for Regenerative Medicine -- Clinical Outlooks for Regenerative Medicine 2012 Marcum's Inaugural MicroCap Conference About NeoStem, Inc. NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, LLC, also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and is enrolling patients … Continue reading →

ORANGE, Calif.--(BUSINESS WIRE)-- A CHOC Childrens research project, under the direction of Philip H. Schwartz, Ph.D., senior scientist at the CHOC Childrens Research Institute and managing director of the facilitys National Human Neural Stem Cell Resource, has been awarded a $5.5 million grant from the California Institute for Regenerative Medicine (CIRM). The grant will be used to develop a stem cell-based therapy for the treatment of mucopolysaccharidosis (MPS I), a fatal metabolic disease that causes neurodegeneration, as well as defects in other major organ systems. Based on a number of medical and experimental observations, children with inherited degenerative diseases of the brain are expected to be among the first to benefit from novel approaches based on stem cell therapy (SCT). Dr. Schwartz explains, While uncommon, pediatric genetic neurodegenerative diseases account for a large burden of mortality and morbidity in young children. Hematopoietic (bone marrow) stem cell transplant (HSCT) can improve some non-neural symptoms of these diseases, but does not treat the deadly neurodegenerative process. Our approach targeting the effects of the disease on organs besides the brain with HSCT and neurodegeneration with a second stem cell therapy specifically designed to treat the brain is a strategy for whole-body treatment of … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading stem cell company focused on developing and commercializing products to treat medical conditions in inflammatory, cardiovascular, orthopedic, and wound healing markets, announced today that it has received transitional pass-through status from the Center for Medicare & Medicaid Services (CMS), with C-Codes being designated for Grafix. Further, the product has been assigned pass-through status under Medicare's outpatient prospective payment system (OPPS), effective July 1, 2012. These codes will assist in facilitating reimbursement when Grafix products are used to treat Medicare patients with acute and chronic wounds in the hospital outpatient department and ambulatory surgical center settings. We are very pleased with CMS, and their decision to assign pass-through codes for our Grafix line of Biosurgery products, said Frank Czworka, Executive Director, Wound Care of Osiris Therapeutics. This step will allow more Medicare patients and their providers to have greater access to these next-generation regenerative medicine products." CMS also issued a preliminary positive decision for the assignment of permanent Healthcare Common Procedure Coding System (HCPCS) Q-codes for Grafix. If the decision is made permanent, it is anticipated that the Q-codes would be available starting in January 2013. The assignment of unique Q-codes will … Continue reading →

SUNRISE, Fla., May 29, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT.OB - News) announced today that it will offer another laboratory training course in partnership with the Ageless Regenerative Institute, an organization dedicated to the standardization of cell regenerative medicine, on Saturday/Sunday June 23-24, 2012. Attendees will participate in hands on, in depth training in laboratory practices in stem cell science at Bioheart, Inc.'s corporate headquarters and clean room in Sunrise, Florida. The course was designed for Laboratory technicians, Students, Physicians and Physician Assistants. "Attendees will graduate from this one-of-a-kind course with an extensive understanding of stem cell science laboratory practices," said Kristin Comella, Chief Scientific Officer, Bioheart, Inc. "Previous attendees described the course as incredibly well orchestrated providing comprehensive know how for laboratory start up." An emerging field with tremendous opportunities, adult stem cell research has been shown to regenerate and repair injured or diseased structures via the release of bioactive tissue growth factors and cytokines. This is the second time that The Ageless Regenerative Institute has partnered with Bioheart, Inc. to provide hands-on training in a stem cell laboratory. This course provides instruction regarding how to grow stem cells and perform quality control testing in an actual cGMP … Continue reading →

EDINBURGH, Scotland, May 29, 2012 /PRNewswire/ -- Research into conditions such as multiple sclerosis and heart and liver disease will benefit from multi-million dollar stem cell research and life sciences facilities opened yesterday by HRH, the Princess Royal. The Princess Royal is to unveil plaques this afternoon at the $85 million Scottish Centre for Regenerative Medicine (SCRM) and $38 million bio-incubator facility, Nine, in Edinburgh. The University of Edinburgh's Scottish Centre for Regenerative Medicine will carry out cutting-edge stem cell research to help find therapies for patients with conditions such as multiple sclerosis, Parkinson's disease, motor neurone disease, and heart and liver diseases. The centre is the first large-scale, purpose-built facility of its kind and provides accommodation for up to 250 stem cell scientists. The centre, funded by the University of Edinburgh, Scottish Enterprise, the Medical Research Council (MRC) and the British Heart Foundation through its Mending Broken Hearts Appeal, was opened by the Princess Royal in her role as Chancellor of the University. It includes the most up-to-date facilities in the UK, which meet the highest guidelines, to manufacture stem cell lines that could be used for patient therapies. Nine, which has been jointly funded by Scottish Enterprise and … Continue reading →

SAN DIEGO, May 29, 2012 (GLOBE NEWSWIRE) -- via PRWEB - Stemedica Cell Technologies, Inc. announced today that its strategic partner in Mexico, Grupo Angeles Health Services, has received approval from Mexico's regulatory agency, COFEPRIS, for a Phase I/II single-blind randomized clinical trial for chronic heart failure. COFEPRIS is the Mexican equivalent of the United States FDA. The clinical trial, to be conducted at multiple hospital sites throughout Mexico, will utilize Stemedica's adult allogeneic ischemia tolerant mesenchymal stem cells (itMSC) delivered via intravenous infusion. The trial will involve three safety cohorts at different dosages, followed by a larger group being treated with the maximum safe dosage. The COFEPRIS approval is the second approval for the use of Stemedica's itMSCs. COFEPRIS approved Stemedica's itMSCs in 2010 for a clinical trial for ischemic stroke. These two trials are the only allogeneic stem cell studies approved by COFEPRIS. Grupo Angeles is a Mexican company that is 100% integrated into the national healthcare development effort. The company is comprised of 24 state-of-the-art hospitals totaling more than 2,000 beds and 200 operating rooms. Eleven thousand Groupo Angeles physicians annually treat nearly five million patients a year. Of these, more than two million are seen as … Continue reading →

THE MAKATI Medical Centers Cancer Center celebrated its first year anniversary and marked the occasion with the launch of its Cellular Therapeutics Laboratory. Present at the ribbon-cutting ceremony were Dr. Eric Flores, head, Spine Clinic and Stem Cell Lab; Rosalie Montenegro, Makati Medical Center president and CEO; Dr. ManuelO. Fernandez Jr., executive vice president and director, Professional Services; Dr. Remedios G. Suntay, director and treasurer, MDI Board; Dr. Benjamin N. Alimurung, medical director; Dr. Francis Chung, scientific officer, Stem Cell Lab; and Augusto P. Palisoc Jr., executive director, president and CEO, MPIC Hospital Group. MAKATIMEDS Cellular Therapeutics Laboratory is managed by experienced scientists with extensive training and is affiliated with the International Society for Cellular Therapy. Stem cell therapy is now being offered at Makati Medical Center (MMC) as potential cure for a wide range of illnesses, from various types of cancer and heart ailments to incurable diseases such as multiple sclerosis, Parkinsons and Alzheimers. Stem cell therapy is believed to be effective in bone marrow transplant for leukemia patients, and with early intervention, yields desirable results among renal and prostate cancer patients. Launched in the first year anniversary of the hospitals cancer center, MMCs Cellular Therapeutics Laboratory is equipped … Continue reading →

28 May 2012 Last updated at 09:14 ET A 54m cutting-edge stem cell research centre in Edinburgh has been officially opened by the Princess Royal. The Royal opened the Scottish Centre for Regenerative Medicine as well as the 24m bio-incubator facility, Nine, in the Edinburgh BioQuarter. Research into conditions such as multiple sclerosis and heart and liver disease will benefit from the new facilities in Little France. The Princess Royal unveiled plaques at the centres. Edinburgh University's Scottish Centre for Regenerative Medicine is the first large-scale, purpose-built facility of its kind and provides accommodation for up to 250 stem cell scientists. The centre, funded by Edinburgh University, Scottish Enterprise, the Medical Research Council (MRC) and the British Heart Foundation through its Mending Broken Hearts Appeal, is being opened by the Princess Royal in her role as Chancellor of Edinburgh University. It includes the most up-to-date facilities in the UK, which meet the highest guidelines, to manufacture stem cell lines that could be used for patient therapies. Nine, which has been jointly funded by Scottish Enterprise and the UK government's department for business, innovation and skills, has 85,000 sq ft of laboratory and office space for both established biotechnology companies and … Continue reading →

Burr, the drummer with Maiden from 1979 until 1982, has been in a wheelchair as a result of multiple sclerosis, which has been attacking his nervous system since before he was diagnosed in 2002. MS reduces the ability of the brain and spinal cord to communicate with each other, resulting in a wide range of potentially severe symptoms. The cause is unknown and there is no cure; but in 2009 researchers made the first breakthrough in reversing symptoms through stem cell therapy. Di'Anno tells Talking Metal Pirate Radio Burr's condition is "not very good at all." - He had a lot to say, read it here. Classic Rock Magazine is an official news provider for antiMusic.com. Copyright Classic Rock Magazine- Excerpted here with permission. antiMUSIC News featured on RockNews.info and Yahoo News ...end The rest is here: Di'Anno Wants Former Iron Maiden Bandmate To Undergo Stem Cell Therapy Recap … Continue reading →

Five UC San Diego scientists have received almost $12 million combined from the California Institute for Regenerative Medicine to pay for stem cell-based research, the university announced today. A team led by Lawrence Goldstein, of the Department of Cellular and Molecular Medicine and director of the UC San Diego Stem Cell Program, was given $1.8 million to continue looking for new methods to find and test possible medications for Alzheimer's disease, according to UCSD. They use reprogrammed stem cells in their work. Dr. Mark Tuszynski, professor of neurosciences and director of the Center for Neural Repair, received $4.6 million to develop more potent stem cell-based treatments for spinal cord injuries. Gene Yeo, assistant professor in the Department of Cellular and Molecular Medicine, was awarded $1.6 million to continue research into treatments for amyotrophic lateral sclerosis. His research hopes to take advantage of recent discoveries about ALS, or Lou Gehrig's disease, which center on mutations in RNA-binding proteins that cause dysfunction and death in neurons. Dr. Eric David Adler, an associate clinical professor of medicine and cardiologist, was granted $1.7 million to screen potential drugs for Danon disease, a type of inherited heart failure that frequently kills patients by their 20s. … Continue reading →